Reference standard for characterization of rosuvastatin

ABSTRACT

Provided are rosuvastatin degradation products and their use as a reference standard (including reference marker) for analysis of rosuvastatin.

CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. application Ser. No.11/001,912, filed Dec. 2, 2004, now U.S. Pat. No. 7,244,844, whichclaims the benefit of U.S. Provisional Application No. 60/526,449 filedon Dec. 2, 2003, the disclosure of which is incorporated by reference inits entirety herein.

FIELD OF THE INVENTION

The present invention relates to rosuvastatin degradation products andtheir use as a reference standard for analysis of rosuvastatin.

BACKGROUND OF THE INVENTION

Statins are currently the most therapeutically effective drugs availablefor reducing low-density lipoprotein (LDL) particle concentration in theblood stream of patients at risk for cardiovascular disease. Thus,statins are used in the treatment of hypercholesterolemia,hyperlipoproteinemia, and atherosclerosis. A high level of LDL in thebloodstream has been linked to the formation of coronary lesions thatobstruct the flow of blood and can rupture and promote thrombosis.Goodman and Gilman, The Pharmacological Basis of Therapeutics, page 879(9th Ed. 1996).

Statins inhibit cholesterol biosynthesis in humans by competitivelyinhibiting the 3-hydroxy-3-methyl-glutaryl-coenzyme A (“HMG-CoA”)reductase enzyme. HMG-CoA reductase catalyzes the conversion of HMG tomevalonate, which is the rate-determining step in the biosynthesis ofcholesterol. Decreased production of cholesterol causes an increase inthe number of LDL receptors and corresponding reduction in theconcentration of LDL particles in the bloodstream. Reduction in the LDLlevel in the bloodstream reduces the risk of coronary artery disease.J.A.M.A. 1984, 251, 351-74.

Currently available statins include lovastatin, simvastatin,pravastatin, fluvastatin, cerivastatin and atorvastatin. Lovastatin(disclosed in U.S. Pat. No. 4,231,938) and simvastatin (disclosed inU.S. Pat. No. 4,444,784) are administered in the lactone form. Afterabsorption, the lactone ring is opened in the liver by chemical orenzymatic hydrolysis, and the active hydroxy acid is generated.Pravastatin (disclosed in U.S. Pat. No. 4,346,227) is administered asthe sodium salt. Fluvastatin (disclosed in U.S. Pat. No. 4,739,073) andcerivastatin (disclosed in U.S. Pat. Nos. 5,006,530 and 5,177,080), alsoadministered as the sodium salt, are entirely synthetic compounds thatare in part structurally distinct from the fungal derivatives of thisclass that contain a hexahydronaphthalene ring. Atorvastatin and two new“superstatins,” rosuvastatin and pitavastatin, are administered ascalcium salts.

Rosuvastatin calcium (monocalcium bis (+)7-[4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylaminopyrimidin)-5-yl]-(3R,5S)-dihydroxy-(E)-6-heptenoate)is an HMG-CoA reductase inhibitor, developed by Shionogi for the oncedaily oral treatment of hyperlipidaemia (Ann Rep, Shionogi, 1996; Directcommunications, Shionogi, 8 Feb. 1999 & 25 Feb. 2000). Rosuvastatincalcium is a superstatin, which can lower LDL-cholesterol andtriglycerides more effectively than first generation drugs. Rosuvastatincalcium has the following chemical formula:

Rosuvastatin calcium is marketed under the name CRESTOR for treatment ofa mammal such as a human. According to the maker of CRESTOR, it isadministered in a daily dose of from about 5 mg to about 40 mg. Forpatients requiring less aggressive LDL-C reductions or who havepre-disposing factors for myopathy, the 5 mg dose is recommended, while10 mg dose is recommended for the average patient, 20 mg dose forpatients with marked hyper-cholesterolemia and aggressive lipid targets(>190 mg/dL), and the 40 mg dose for patients who have not beenresponsive to lower doses.

U.S. Pat. No. 5,260,440 discloses and claims rosuvastatin, its calciumsalt (2:1), and its lactone form. The process of the '440 patentprepares rosuvastatin by reacting4-(4-fluorophenyl)-6-isopropyl-2-(N-methyl-N-methylsulfonylamino)-5-pyrimidinecarbaldehydewith methyl(3R)-3-(tert-butyldimethylsilyloxy)-5-oxo-6-triphenylphosphoranylidenehexanate in acetonitrile under reflux. The silyl group is then cleavedwith hydrogen fluoride, followed by reduction with NaBH₄ anddiethylmethoxyborane in THF to obtain a methyl ester of rosuvastatin.

The ester is then hydrolyzed with sodium hydroxide in ethanol at roomtemperature, followed by removal of ethanol and addition of ether, toobtain the sodium salt of rosuvastatin. The sodium salt is thenconverted to the calcium salt. The sodium salt is dissolved in water andmaintained under a nitrogen atmosphere. Calcium chloride is then addedto the solution, resulting in precipitation of rosuvastatin calcium(2:1). The process for preparation of the intermediates disclosed in the'440 patent is incorporated herein by reference.

U.S. Pat. No. 6,316,460 discloses a pharmaceutical composition ofrosuvastatin. The pharmaceutical compositions contain rosuvastatin orits salt and a multivalent tribasic phosphate salt.

The product mixture of a reaction rarely is a single compound pureenough to comply with pharmaceutical standards. Side products andbyproducts of the reaction and adjunct reagents used in the reactionwill, in most cases, be present. At certain stages during processing ofthe rosuvastatin contained in the product mixture into an activepharmaceutical ingredient (“API”), the rosuvastatin must be analyzed forpurity, typically by HPLC or GC analysis, to determine if it is suitablefor continued processing or ultimately for use in a pharmaceuticalproduct. The rosuvastatin does not need to be absolutely pure. Absolutepurity is a theoretical ideal that is unattainable. Rather, there arepurity standards intended to ensure that an API is not made less safefor clinical use because of the presence of impurities. In the UnitedStates, the Food and Drug Administration guidelines recommend thatapplicants limit some impurities to below 0.1%.

Generally, side products, byproducts and adjunct reagents (collectively“impurities”) are identified spectroscopically and by other physicalmethods and then the impurities are associated with a peak position in achromatogram (or a spot on a TLC plate). (Strobel p. 953) (Strobel, H.A.; Heineman, W. R., Chemical Instrumentation: A Systematic Approach,3^(rd) dd. (Wiley & Sons: New York 1989)). Thereafter, the impurity canbe identified by its position in the chromatogram, which isconventionally measured in minutes between injection of the sample onthe column and elution of the particular component through the detector,known as the “retention time.” This time period varies daily based uponthe condition of the instrumentation and many other factors. To mitigatethe effect that such variations have upon accurate identification of animpurity, practitioners use “relative retention time” (“RRT”) toidentify impurities. (Strobel p. 922). The RRT of an impurity is itsretention time divided by the retention time of some reference marker.In theory, rosuvastatin itself could be used as the reference marker,but as a practical matter it is present in such overwhelming proportionin the mixture that it tends to saturate the column, leading toirreproducible retention times, i.e., the maximum of the peakcorresponding to rosuvastatin tends to wander (Strobel FIG. 24.8(b) p.879, contains an illustration of the sort of asymmetric peak that isobserved when a column is overloaded). Thus, it is sometimes desirableto select an alternative compound that is added to, or is present in,the mixture in an amount significant enough to be detectable andsufficiently low as not to saturate the column and to use that compoundas the reference marker.

Researchers and developers in drug manufacturing understand that acompound in a relatively pure state can be used as a “referencestandard” (a “reference marker” is similar to a reference standard butit is used for qualitative analysis) to quantify the amount of thecompound in an unknown mixture. When the compound is used as an“external standard,” a solution of a known concentration of the compoundis analyzed by the same technique as the unknown mixture. (Strobel p.924, Snyder p. 549) (Snyder, L. R.; Kirkland, J. J. Introduction toModern Liquid Chromatography, 2nd ed. (John Wiley & Sons: New York1979)). The amount of the compound in the mixture can be determined bycomparing the magnitude of the detector response. See also U.S. Pat. No.6,333,198, incorporated herein by reference.

The reference standard compound also can be used to quantify the amountof another compound in the mixture if the “response factor,” whichcompensates for differences in the sensitivity of the detector to thetwo compounds, has been predetermined. (Strobel p. 894). For thispurpose, the reference standard compound may be added directly to themixture, in which case it is called an “internal standard.” (Strobel p.925, Snyder p. 552).

The reference standard compound can even be used as an internal standardwhen the unknown mixture contains some of the reference standardcompound by using a technique called “standard addition,” wherein atleast two samples are prepared by adding known and differing amounts ofthe internal standard. (Strobel pp. 391-393, Snyder pp. 571, 572). Theproportion of detector response due to the reference standard compoundthat is originally in the mixture can be determined by extrapolation ofa plot of detector response versus the amount of the reference standardcompound that was added to each of the samples to zero. (e.g. Strobel,FIG. 11.4 p. 392).

The present invention provides a rosuvastatin degradation product thatcan be used as a reference standard for analysis of rosuvastatin.

SUMMARY OF THE INVENTION

In one aspect, the present invention provides a rosuvastatin degradationproduct having the following structure:

In another aspect, the present invention provides a rosuvastatindegradation product having the following structure:

In another aspect, the present invention provides a rosuvastatindegradation product having the following structure:

wherein M is an alkali or alkaline earth metal.

In another aspect, the present invention provides a rosuvastatindegradation product having the following structure:

wherein M is an alkali or alkaline earth metal. Preferably M is calcium.The calcium salt may be converted to lactone form by combining it withacetonitrile and hydrochloric acid; or to free acid comprisingdissolving the calcium salt in a mixture of acetonitrile and water, andcontacting the calcium salt with a silica column.

In another aspect the present invention provides a lactone form of arosuvastatin degradation product having the following structure:

In another aspect, the present invention provides a lactone form of arosuvastatin degradation product having the following structure:

In another aspect, the present invention provides a process forconverting the lactone to a calcium salt comprising hydrolyzing thelactone under aqueous basic conditions, and reacting the hydrolyzedlactone with a source of calcium.

In another aspect, the present invention provides a process forconverting the lactone to free acid form comprising hydrolyzing thelactone under aqueous basic conditions to obtain a metal salt andcontacting the metal salt with a silica column.

Preferably the degradation product is about 95% free % area by HPLC ofits corresponding stereoisomer at position 6. The rosuvastatindegradation product may be isolated or purified.

In another aspect, the present invention provides a method for analyzinga sample of rosuvastatin comprising the steps of:

-   a) performing chromatography on the sample to obtain data; and-   b) comparing the data with the chromatography data of the    degradation product.

In another aspect the present invention provides a process for preparingthe degradation product comprising the step of irradiating with visiblelight rosuvastatin acid, rosuvastatin alkali or alkaline earth metalsalt or rosuvastatin lactone.

In another aspect, the present invention provides a method fordetermining the retention time of a chromatography column forrosuvastatin, comprising the steps of carrying out chromatography withthe following compound as a standard,

wherein R₁ and R₂ are independently hydrogen or a hydrolyzableprotecting group; R₃ is hydrogen, a C₁ to C₄ alkyl group, or an alkalior alkaline earth metal; or wherein C¹ and C⁵ form a lactone.

BRIEF DESCRIPTION OF THE FIGURES

FIG. 1 is an HPLC chromatogram of Compound VI.

FIG. 2 is an HPLC chromatogram of Compound VII.

FIG. 3 is an HPLC chromatogram of a mixture of rosuvastatin, CompoundVI, and Compound VII.

FIG. 4 is an HPLC chromatogram of the Purity of Compound VI.

FIG. 5 is a chromatogram of purity of Compound VII.

FIG. 6 is a chromatogram of a mixture of rosuvastatin Ca, Compound VIand Compound VII.

FIG. 7 is a chromatogram of rosuvastatin Ca spiked with Compound VI andCompound VII.

DETAILED DESCRIPTION OF THE INVENTION

As used herein, the term “reference standard” refers to a compound thatmay be used both for quantitative and qualitative analysis of an activepharmaceutical ingredient. For example, the retention time of thecompound in HPLC allows for setting a relative retention time, thusmaking qualitative analysis possible. The concentration of the compoundin solution before injection into an HPLC column allows for comparisonof the areas under the peaks in an HPLC chromatogram, thus makingquantitative analysis possible.

A “reference marker” is used in qualitative analysis to identifycomponents of a mixture based upon their position, e.g. in achromatogram or on a Thin Layer Chromatography (TLC) plate (Strobel pp.921, 922, 953). For this purpose, the compound does not necessarily haveto be added to the mixture if it is present in the mixture. A “referencemarker” is used only for qualitative analysis, while a referencestandard may be used for quantitative or qualitative analysis, or both.Hence, a reference marker is a subset of a reference standard, and isincluded within the definition of a reference standard.

Although some of the knowledge of those in the art regarding referencestandards has been described in general terms up to this point, thoseskilled in the art also understand that the detector response can be,for example, the peak heights or integrated peak areas of a chromatogramobtained, e.g. by UV or refractive index detection, from the eluent ofan HPLC system or, e.g. flame ionization detection or thermalconductivity detection, from the eluent of a gas chromatograph, or otherdetector response, e.g. the UV absorbence, of spots on a fluorescent TLCplate. The position of the reference standard may be used to calculatethe relative retention time for rosuvastatin and other impurities.

When rosuvastatin calcium is exposed to visible light irradiation,degradation products of rosuvastatin are obtained, which can be used asa reference standard. The two degradation products are diastereomericcyclic products (II) and (III) with the creation of an additionalasymmetric center in position 6 as follows:

In addition to rosuvastatin calcium, other forms of rosuvastatin may beirradiated, including the lactone, free acid and salts such as sodiumsalt.

The irradiation may be performed in solution or in solid state. Whenirradiating a solution, the irradiation may be performed at preferablyfrom about room temperature up to about reflux temperature. The organicsolvent used for dissolution may be either polar protonic (C₁ to C₄alcohol such as methanol or ethanol) or aprotonic (acetonitrile,tetrahydrofuran) in a mixture with water. Visible light irradiation ofabout 750 w at about 35° C. of aqueous acetonitrile solution ofrosuvastatin calcium for about 7 hours gives a mixture of compounds (IIand III) in the ratio 1:1. When irradiating in the solid state, thetemperature is preferably from about 20 EC to about 100 EC. One of skillin the art may yet choose a narrow spectrum within these spectrums or amixture of various spectrums. Based on the structural guidance providedherein of the various degradation products, one of skill in the art mayprepare a synthetic route to obtain the degradation products.

In another embodiment, the corresponding lactone is obtained, either byirradiating the lactone form of rosuvastatin or by preparing the lactonefrom Compounds II and III to obtain the corresponding Compounds IV and Vwhich can be used as a reference standard. Compound IV has the following¹H NMR (300 MHz, CDCl₃) δ (ppm): 1.24, 1.34, 1.68, 2.47, 2.53, 2.64,3.15, 3.35, 3.46, 3.56, 3.60, 4.28, 4.45, 6.99, 7.14, 8.31; ¹³C NMR (75MHz, CDCl₃) δ (ppm): 20.87, 21.26, 23.29, 31.41, 33.26, 34.03, 38.23,42.07, 43.00, 62.23, 74.53, 115.61, 116.08 (J=26 Hz), 116.25 (J=22 Hz),129.08, 128.91 (J=9 Hz), 139.28 (J=8 Hz), 157.64, 157.86, 163.96 (J=253Hz), 169.47, 174.48; FAB+m/z (MH⁺): 464. Compound V has the following¹NMR (300 MHz, CDCl₃) δ (ppm): 1.24, 1.29, 1.52, 1.70, 2.58, 3.02, 3.21,3.27, 3.41, 3.55, 3.60, 4.26, 4.78, 7.05, 7.12, 8.34; FAB+m/z (MH⁺):464.

The preparation of the corresponding lactone compounds IV and V fromcompound II and III includes dissolving compound II and III in asuitable solvent and forming a lactone ring for example with aqueoushydrochloric acid. Other acids may be used to form a lactone. A suitablesolvent for preparation of the lactone from Compound II or III isdichloromethane, chloroform, acetonitrile or tetrahydrofuran.Preferably, the suitable solvent is acetonitrile. To recover theproduct, the solvent may be removed by any conventional process, such asevaporation. Obtained compounds IV and V can be separated by methodssuch as column chromatography and crystallization.

The preparation of the corresponding lactone compounds IV and V fromrosuvastatin lactone may also be performed by visible light irradiationin the same solvents. The irradiation characteristics are as describedabove. The lactone compounds IV and V may be hydrolyzed with anequivalent amount of an aqueous base such as sodium or calcium hydroxideto obtain the corresponding salts in the presence of a solvent.Preferably, the solvent is acetonitrile. In one embodiment, the lactonesare hydrolyzed with an aqueous solution of sodium hydroxide inacetonitrile, followed by removal of acetonitrile and addition of asource of calcium such as calcium chloride.

The lactone forms IV and V can be hydrolyzed with a base to obtain saltsand thereafter converted to acid forms VI and VII, respectively, whichcan be used as a reference standard. The conversion of the lactones tosalts may be carried out by using a basic aqueous solution. In oneembodiment, the lactone is dissolved in a mixture of acetonitrile and anaqueous NaOH solution. The acetonitrile is then removed and a source ofcalcium such as calcium chloride is added to precipitate the calciumsalt.

The acid forms are obtained after purifying the salt products by columnchromatography on silica gel (as described in example 1). It is believedthat the acidity of the silica column is responsible for the conversion.Compound VI has the following ¹H NMR (600 MHz, CDCl₃+CD₃OD 5:1) δ (ppm):1.25, 1.33, 1.39, 1.58, 2.22, 2.80, 2.89, 3.36, 3.52, 3.58, 3.61, 3.95,7.01, 7.09, 8.26; ¹³C NMR (150 MHz, CDCl₃+CD₃OD 5:1) δ (ppm): 21.14,21.31, 23.32, 31.56, 33.47, 40.15, 42.16, 42.97, 44.62, 68.99, 71.45,115.17 (J=21 Hz), 116.32 (J=22 Hz), 117.77, 128.87 (J=9 Hz), 129.20,142.34 (J=8 Hz), 157.71, 158.57, 164.26 (J=251 Hz), 174.30; Cl+m/z(MH⁺): 482. Compound VII has the following ¹NMR (600 MHz, CDCl₃+CD₃OD5:1) δ (ppm): 1.24, 1.31, 1.43, 2.25, 2.95, 3.05, 3.19, 3.30, 3.56,3.60, 3.85, 4.03, 7.02, 7.08, 7.31; ¹³C NMR (150 MHz, CDCl₃+CD₃OD 5:1) δ(ppm): 21.15, 21.23, 22.98, 31.22, 33.36, 38.83, 42.08, 43.45, 68.82,73.86, 114.95 (J=21 Hz), 116.31 (J=21 Hz), 117.41, 128.56 (J=8 Hz),128.91, 142.02 (J=8 Hz), 157.58, 158.45, 164.28 (J=252 Hz), 173.19, 178;Cl+m/z (MH⁺): 482.

The various forms of the degradation product may be purified so thatonly one stereoisomer is present. The R stereoisomer at position 6 ispreferably at least about 95% free of the S stereoisomer % area by HPLC.Conversely, the S stereoisomer at position 6 is preferably at leastabout 95% free of the R stereoisomer % area by HPLC. Purification may beperformed by column chromatography, TLC, HPLC, or other knownpurification methods.

Instruments

For chromatography, aluminum oxide or, preferably, silica gel may beused for packing. As for the eluent, different organic solvents ormixtures thereof may be used. Ethyl acetate is preferred.

Compounds II and III, isolated as corresponding acids (VI and VII),lactones (IV and V) can be investigated with ¹NMR, ¹³C NMR, COSY NMR andmass spectroscopic analyses to determine their structures.

EXAMPLES Example 1 Preparation of Rosuvastatin Degradation Products byIrradiation of Rosuvastatin (Ca Salt)

-   1. Rosuvastatin (Ca-salt) (4.0 g) was dissolved in a mixture    acetonitrile-water (380 ml-140 ml) and irradiated with visible light    (750 w, 35° C.) for 7 hours. Acetonitrile and water were evaporated    under vacuum.-   2. The obtained solid was dissolved in 40 ml of acetonitrile and 40    ml of 1N hydrochloric acid was added. The mixture was stirred at    room temperature overnight. After evaporation of acetonitrile and    water, and drying under vacuum, the obtained products were separated    by column chromatography on silica gel (eluent hexane-ethyl acetate    1:2), giving lactone IV (0.8 g) and lactone V (0.6 g). TLC on silica    gel, eluent hexane-ethyl acetate (1:2) R_(f)=0.30 for Compound IV,    R_(f)=0.25 for Compound V.    Compound IV

¹H NMR ¹³C NMR (CDCl₃) (CDCl₃) Number Atom Δ Δ J(Hz) 1  169.47 2  2.53,2.64 38.23 3  4.28 62.23 4  1.68 34.03 5  4.45 74.53 6  3.15 43.00 7 2.47, 3.46 23.29 2′ 157.64 4′ 157.86 5′ 115.61 6′ 174.48 7′ 3.35 31.418′ 1.24, 1.34 21.36, 20.87 9′ 3.60 33.26 10′  3.56 42.07 1″ 129.08 2″139.28 8 3″ 6.99 116.25 22 4″ 163.96 253 5″ 7.14 116.08 26 6″ 8.31128.91 9Compound V

¹H NMR (CDCl₃) Number Atom Δ 2 2.58 3 4.26 4 1.52, 1.70 5 4.78 6 3.41 73.02, 3.21  7′ 3.27  8′ 1.24, 1.29  9′ 3.60 10′  3.55  3″ 7.05  4″  5″7.12  6″ 8.34

-   3. Lactone IV (0.8 g) was dissolved in acetonitrile, and 1N aqueous    sodium hydroxide (4 ml) was added. The mixture was stirred at room    temperature overnight. After evaporation of acetonitrile and water,    and drying under vacuum, the obtained product was purified by column    chromatography on silica gel (eluent dichloromethane-methanol 65    ml:10 ml), giving pure Compound VI (0.4 g).    Compound VI (Corresponding Acid of Compound IV)

¹H NMR ¹³C NMR (CDCl₃ + CD₃OD 5:1) (CDCl₃ + CD₃OD 5:1) Number Atom Δ ΔJ(Hz) 1  2  2.22 42.97 3  3.95 68.99 4  1.39/1.58 40.15 5  3.58 71.45 6 2.89 44.62 7  2.80/3.52 23.32 2′ 157.71 4′ 158.57 5′ 117.77 6′ 174.30 7′3.36 31.56 8′ 1.25/1.33 21.14/21.31 9′ 3.61 33.47 10′  3.58 42.16 1″129.20 2″ 142.34 8 3″ 7.01 116.32 22 4″ 164.26 251 5″ 7.09 115.17 21 6″8.26 128.87 9

-   4. Analogously, Compound VII (0.3 g) was obtained from lactone V.    Compound VII (Corresponding Acid of Compound V)

¹H NMR ¹³C NMR (CDCl₃ + CD₃OD 5:1) (CDCl₃ + CD₃OD 5:1) Number Atom Δ ΔJ(Hz) 1  178 2  2.25 42.08 3  4.03 68.82 4  1.43 38.83 5  3.85 73.86 6 3.05 43.45 7  2.95/3.19 22.98 2′ 157.58 4′ 158.45 5′ 117.41 6′ 173.19 7′3.30 31.22 8′ 1.24/1.31 21.15/21.23 9′ 3.60 33.36 10′  3.56 42.08 1″128.91 2″ 142.02 8 3″ 7.02 116.31 21 4″ 164.28 252 5″ 7.08 114.95 21 6″8.31 128.56 8

Example 2 Preparation of Rosuvastatin Degradation Products byIrradiation of Rosuvastatin Lactone

-   1. Rosuvastatin lactone (2.0 g) was dissolved in 200 ml of    acetonitrile and irradiated with visible light (750 w, 35° C.) for 7    hours. After evaporation of the acetonitrile, and drying under    vacuum, the obtained products were separated by column    chromatography on silica gel (eluent hexane-ethyl acetate 1:2),    giving lactone IV (1.1 g) and lactone V (0.6 g).-   2. Lactone IV (1.0 g) was dissolved in 5 ml of acetonitrile and 2 ml    of 1N aqueous NaOH was added. The mixture was stirred at room    temperature for 4 hours. After evaporation of acetonitrile, 1 ml of    2N aqueous CaCl₂ was added, and the mixture was stirred for 1 hour    at room temperature. The precipitate was filtered and dried under    vacuum giving Compound II.-   3. Analogously, Compound III was obtained from lactone V.

Example 3 HPLC Impurity Profile Determination of Rosuvastatin Calcium

The purity of Compounds IV, V, VI and VII is determined by HPLCanalysis.

HPLC

-   Column: C18-   Eluent: Gradient of Formate buffer and Acetonitrile-   Flow: 1 ml/min-   Detector: 245 nm-   Sample volume: 10 ul-   Diluent: Acetonitrile:Water=50:50

Mobile phase composition and flow rate may be varied in order to achievethe required system suitability.

Sample Preparation

About 10 mg of rosuvastatin calcium sample is weighed in a 20 ml ambervolumetric flask. The sample is dissolved with 10 ml acetonitrile anddiluted to volume with water.

Standard Preparation

About 10 mg of each Compounds IV, V, VI and VII are weighed in a 20 mlamber volumetric flask, dissolved with 10 ml acetonitrile and diluted tovolume with water. 1 ml of prepared solution is diluted to 100 ml withdiluent.

Method

The freshly prepared sample solutions are injected into thechromatograph, and the chromatogram of the sample is continued up to theend of the gradient. The areas for each peak in each solution isdetermined using a suitable integrator.

Having thus described the invention with reference to particularpreferred embodiments and illustrated it with Examples, those in the artcan appreciate modifications to the invention as described andillustrated that do not depart from the spirit and scope of theinvention as disclosed in the specification. The Examples are set forthto aid in understanding the invention but are not intended to, andshould not be construed to, limit its scope in any way. The examples donot include detailed descriptions of conventional methods. Allreferences mentioned herein are incorporated in their entirety.

1. A rosuvastatin degradation product having the following structure:


2. A mixture comprising rosuvastatin degradation product I

and rosuvastatin degradation product II

wherein rosuvastatin product II is less than 5% area by HPLC in relationto product I in the mixture.